Donepezil and rivastigmine in the treatment of Alzheimer's disease: A best-evidence synthesis of the published data on their efficacy and cost-effectiveness

Clinical Therapeutics

Volumn 24, Issue 6, 2002, Pages 862-886

  Wolfson, Christina ^a   Oremus, Mark ^a   Shukla, Vijay ^a   Momoli, Franco ^a   Demers, Louise ^a   Perrault, Anne ^a   Moride, Yola ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Best evidence synthesis; Donepezil; Economic evaluation; Efficacy; Rivastigmine

Indexed keywords

CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; ADULT; COGNITION; COGNITIVE DEFECT; CONFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; ECONOMIC ASPECT; EVALUATION; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NATIONAL HEALTH SERVICE; PHASE 4 CLINICAL TRIAL; PUBLICATION; SCORING SYSTEM; STROKE; UNITED STATES; VERTIGO;

AGED; ALZHEIMER DISEASE; CANADA; CARBAMATES; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; HUMANS; INDANS; MIDDLE AGED; MULTICENTER STUDIES; PHENYLCARBAMATES; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0036302138     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80004-2     Document Type: Article

References (54)

1. Canadian Study of Health and Aging: Methods and prevalence of dementia
2. The incidence of dementia in Canada
3. Net economic costs of dementia in Canada
4. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician
5. Essential components of systematic reviews of Alzheimer's disease drug trials
6. Why do we need systematic overviews of randomized trials?
7. How consumers and policymakers can use systematic reviews for decision making
8. Agreement among reviewers of review articles
9. Assessing the societal impact of acetylcholinesterase inhibitor therapies
10. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
11. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
12. Donepezil improves cognition and global function in Alzheimer disease, a 15-week, double-blind, placebo-controlled study
13. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
14. The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
15. The effects of donepezil in Alzheimer's disease - Results from a multinational trial
16. Donepezil therapy in clinical practice: A randomized crossover study
17. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease
18. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan
19. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
20. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
21. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
22. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
23. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study
24. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease
25. Donepezil in Alzheimer's disease: Eighteen month results from Southampton Memory Clinic
26. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression
27. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease
28. The Alzheimer's Disease Assessment Scale: An instrument for assessing treatment efficacy
29. Clinical global impressions in Alzheimer's clinical trials
30. The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease
31. Clinical Dementia Rating (CDR)
32. A new rating scale for dementia syndromes
33. The Neuropsychiatric Inventory: Comprehensive assessment in psychopathology in dementia
34. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: The Neuropsychiatric Inventory Caregiver Distress Scale
35. Measurement of quality-of-life changes in patients with Alzheimer's disease
36. The Global Deterioration Scale for assessment of primary degenerative dementia
37. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada
38. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: A Markov model
39. Pharmacotherapy for people with Alzheimer's disease: A Markov-cycle evaluation of five years' therapy using donepezil
40. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
41. Factors affecting the economic attractiveness of cognitive enhancers in Alzheimer's disease
42. An economic evaluation of donepezil in the treatment of Alzheimer's disease
43. Donepezil use in managed Medicare: Effect on health care costs and utilization
44. Estimating long-term cost savings from treatment of Alzheimer's disease. A modelling approach
45. Potential savings in the cost of caring for Alzheimer's disease: Treatment with rivastigmine
46. Savings in the cost of caring for patients with Alzheimer's disease in Canada: An analysis of treatment with rivastigmine
47. Review of outcome measurement instruments in Alzheimer's disease drug trials: Introduction
48. Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of functional and quality of life scales
49. Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of behavior and mood scales
50. Review of outcome measurement instruments in Alzheimer's disease drug trials: Psychometric properties of global scales